Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Post by TeddyTenBagson Apr 27, 2021 5:39pm
340 Views
Post# 33079247

Surpise Surprise - NAsdaq Disappoints

Surpise Surprise - NAsdaq DisappointsMany people likely got burned today. As I said many times before - Nasdaq does nothing for the value of the company. The only thing that's going to be a catalyst for this stock are positive trial results to advance the current pipeline, partnerships with big pharma and commercialization of medecines.

Everyone was pumping that the WSB boys would take this to the moon etc. etc. Hanging your hopes on a bunch of retail investors is a poor strategy and there were a lot more losers than winners today.

I'm not a basher by any means. I too was hoping to see this go to the moon, but also recognize that the market cap of the company makes no sense and took some money off the table. If the markets crash, this will get hit hard.

All the pumping has probably done more harm than good for the stock.
<< Previous
Bullboard Posts
Next >>